German Inclisiran Network: Retrospective Registry of Patients Being Treated With the siRNA Inclisiran in Germany
NCT ID: NCT05438069
Last Updated: 2022-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2020-12-11
2025-12-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941
Adherence and Persistence to Inclisiran Among Early Users in Germany
NCT05870657
Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study
NCT06958315
Patterns of Inclisiran Use in the Real World: An Analysis of US Databases
NCT07023445
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
NCT05888103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with elevated LDL-cholesterol (hypercholesterolemia)
Application of si RNA Inclisiran to reduce serum LDL-cholesterol levels.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients 18 years and older
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitätsklinikum Leipzig
OTHER
Charite University, Berlin, Germany
OTHER
Technische Universität Dresden
OTHER
Deutsches Herzzentrum Muenchen
OTHER
University of Rostock
OTHER
Ruhr University of Bochum
OTHER
Universitätsmedizin Mannheim
OTHER
LMU Klinikum
OTHER
Jena University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oliver Weingärtner
Clinical Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Weingaertner, MD
Role: PRINCIPAL_INVESTIGATOR
Jena University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jena University Hospital
Jena, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-2429
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.